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Abstract 
The main surgical treatment for melanoma consists in wide surgical excision of the primary lesion and the sentinel 
node but in recent times management of melanoma is rapidly evolving with the introduction of new systemic 
therapies, like BRAF inhibitors, MEK inhibitors and antibodies anti-PD-1 that show good results in controlling even 
advanced stages of the disease. This review aims to present data for the optimal surgical management of patients 
with malignant melanoma. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Surgical removal was the mainstay of therapy 
in early melanoma, and historically there has been 
only a marginal role for surgery in managing patients 
with regional or distant metastases, even if some 
Authors suggested that metastasectomy could 
improve survival in stage IV melanoma if compared to 
non-surgical therapy [1]. In present times 
management of melanoma is rapidly evolving with the 
introduction of new systemic therapies, like BRAF 
inhibitors, MEK inhibitors and antibodies anti-PD-1 
that show good results in controlling even advanced 
stages of the disease [2], [3]. It’s easy to forecast that 
new treatment algorithms will be developed to utilise 
all new drugs, but there’s still much to debate about 
the role of surgical treatment in combination with the 
most recent discoveries in biological therapies. 
 
 
Management of primary lesion 
 
The main surgical treatment for invasive 
malignant melanoma consists of complete surgical 
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excision and removal and examination of the first 
draining lymph node possibly affected by metastatic 
disease. Surgical margins to be removed are based 
on the maximal melanoma Breslow thickness of the 
melanoma [4]. Usually, all suspicious pigmented 
lesions should be removed with a clear clinical margin 
of least 2mm but not exceeding 5 mm not to damage 
the lymphatic drainage to be assessed by a later 
SLNB. Usually, the excision should go through the 
skin and subcutaneous tissue and stop to the 
fascia/periosteum/ perichondrium, only for suspected 
melanoma in situ surgical excision could stop at the 
superficial subcutaneous tissue [5]. Partial biopsies 
are to be avoided mainly to not under stage the lesion.  
For melanoma in situ, according to a late 
expert consensus statement, an excision margin of 5 
mm is considered sufficient to have a radical 
treatment. However, more recent data recommends 
excisions up to 9 mm to obtain clear histological 
margins [5], [6]. There is no indication to widen 
surgical margins if histological free margins have 
already been achieved.  
For invasive melanomas with less than 1 mm 
thickness, a 1 cm surgical margin is considered a 
sufficient margin according to three randomised 
control trials (RCTs) [7], [8], [9], [10]. For intermediate 
and thick melanomas, many RCTs comparing narrow 
(1 cm) and wide excision (up to 5 cm) have been 
published. A recent meta-analysis found no difference 
in overall survival (HR 1.09; 95% CI 0.98 – 1.22; p = 
0.1) between patients treated with narrow or wide 
excision, nor in loco-regional recurrence (HR 1.10; 
95% CI 0.96 – 1.26; p = 0.2). However, in a subgroup 
analysis including four trials only, reporting on 
melanoma-specific survival wide excision was favored 
HR 1.17 (95% CI 1.03 – 1.34; p = 0.02) [11], [12], [13]. 
Surgical excision can in almost every case be 
performed under local anaesthesia and local flaps 
should be performed to cover after wide excision only 
if the surgeon is confident that histologically free 
margins have been achieved. 
 
 
Sentinel lymph node biopsy and 
Complete lymph node dissection 
 
Sentinel node biopsy (SLNB) is the surgical 
procedure where the sentinel lymph node is identified 
and then removed using a radioactive tracer or a 
biological pigment and could be made even in small 
hospitals not needing advanced technological 
resources. SLNB became popular in the 1990s 
because it was supposed that with lymph node 
metastases a block dissection of their nodes would 
have improved survival but the two most important 
long-term prospective randomised trials of SLNB 
(MSLT1 and MSLT2) showed that SLNB and 
subsequent completion lymphadenectomy does not 
improve 10-year melanoma-specific survival [14], [15] 
nevertheless the treatment is still offered because it 
can detect occult disease and improve staging and 
prognosis [16]. The complication rate associated with 
SLNB is approximately 10% [14]. SNB has a false 
negative rate of approximately 10 – 20% [17] A 
positive SN has been found in approximately 5% of 
melanomas ≤ 1 mm thickness and in approximately 
14 – 20% in intermediate-thickness melanomas [18], 
[19], [20] thus SLNB may be considered for patients 
with melanomas with a thickness from 0.8 to 1.0 mm 
or less than 0.8 mm thickness with ulceration, 
classified as T1b lesion, or for intermediate-thickness 
melanomas as reported in AJCC 8th edition [18]. For 
melanomas > 4 mm thickness, SLNB could be 
proposed only for staging because for potential 
disease control its therapeutic benefit is perhaps more 
limited. In certain cases of very thick melanomas, 
imaging could archive an appropriate staging, and 
thus surgery could be avoided [21]. 
Complete lymph node dissection (CLND) was 
considered a cornerstone in the management of 
melanoma patients with a positive SLNB both to 
prevent the melanoma from spreading and to attain 
accurate staging [22]. Two RCTs have been 
published: DeCOG and MSLT-2 comparing the CLND 
with observation after positive SNB. Even if DeCOG 
was stopped prematurely and the study finished 
underpowered, it didn't find any differences in survival. 
The MSLT-2 meta-analysis compared immediate 
CLND with observation / delayed CLND and also 
showed no survival benefit from CLND. However, 
melanoma-specific survival was higher after 
immediate CLND compared with delayed CLND in 
patients with nodal metastasis (HR = 0.63, 95% CI = 
0.35 – 0.74, p = 0.0004) [15], [23].  
Review studies reported a complication rate 
after CLND variable between 24%-37% and a worse 
quality of life after CLND compared with SNB only so 
appears to be important to avoid completion 
lymphadenectomy to prevent unnecessary 
complications [15], [24], [25]. 
 
 
Conclusions 
 
Survival for patients with invasive melanoma 
still depends mostly on early diagnosis and surgery 
maintain his undisputed therapeutic role in small and 
intermediate lesions.  
The role of surgery remains to be determined 
with advanced lesions and lymph nodal metastasis 
because is unclear if there is a benefit with node 
dissection compared with observation in combination 
with adjuvant treatment such as BRAF / MEK 
inhibition or PD-1 inhibition. 
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Treatment for invasive melanoma confirms to 
be a complex and multidisciplinary task that require 
oncologists and surgeons cooperation to guide 
treatment decisions.  
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